The Use of Donation after Cardiac Death Allografts Does Not Increase Recurrence of Hepatocellular Carcinoma

American Journal of Transplantation

Volumn 15, Issue 10, 2015, Pages 2704-2711

  Croome, K P ^a   Lee, D D ^a   Burns, J M ^a   Musto, K ^a   Paz, D ^a   Nguyen, J H ^a   Perry, D K ^a   Harnois, D M ^a   Taner, C B ^a  

^a MAYO CLINIC   (United States)

Author keywords

Donors and donation: donation after brain death (DBD); donors and donation: donation after circulatory death (DCD); liver disease: malignant, ischemia reperfusion injury (IRI)

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BRAIN DEATH; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DISEASE COURSE; DONATION AFTER BRAIN DEATH; DONATION AFTER CARDIAC DEATH; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ORGAN DONOR; OVERALL SURVIVAL; PERINEURAL INVASION; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSARTERIAL CHEMOEMBOLIZATION; TUMOR VOLUME; AGED; ALLOGRAFT; ALLOTRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; DEATH; DONOR; DONOR SELECTION; ETIOLOGY; LIVER NEOPLASMS; MORTALITY; PROCEDURES; SURVIVAL ANALYSIS; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ALLOGRAFTS; BRAIN DEATH; CARCINOMA, HEPATOCELLULAR; DEATH; DONOR SELECTION; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84941934547     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13306     Document Type: Article

References (27)

1. Halazun KJ, Patzer RE, Rana AA, et al., Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 2014; 60: 1957-1962.
2. Goldberg D, French B, Abt P, Feng S, Cameron AM,. Increasing disparity in waitlist mortality rates with increased model for endstage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl 2012; 18: 434-443.
3. Washburn K, Edwards E, Harper A, Freeman R,. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1643-1648.
4. Jay C, Ladner D, Wang E, et al., A comprehensive risk assessment of mortality following donation after cardiac death liver transplant-An analysis of the national registry. J Hepatol 2011; 55: 808-813.
5. Grewal HP, Willingham DL, Nguyen J, et al., Liver transplantation using controlled donation after cardiac death donors: An analysis of a large single-center experience. Liver Transpl 2009; 15: 1028-1035.
6. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM,. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419-425.
7. Croome KP, Marotta P, Wall WJ, et al., Should a lower quality organ go to the least sick patient? Model for End-Stage Liver Disease score and donor risk index as predictors of early allograft dysfunction. Transplant Proc 2012; 44: 1303-1306.
8. Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R,. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl 2013; 19: 1214-1223.
9. Taner CB, Bulatao IG, Perry DK, et al., Asystole to cross-clamp period predicts development of biliary complications in liver transplantation using donation after cardiac death donors. Transpl Int 2012; 25: 838-846.
10. Taner CB, Bulatao IG, Willingham DW, et al., Events in procurement as risk factors for development of ischeminc cholangiopathy in liver transplantation using donation after cardiac death donors. Liver Transpl 2012; 18: 101-112.
11. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al., Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790.
12. Toso C, Trotter J, Wei A, et al., Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107-1115.
13. Fine J, Gray R,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
14. Croome KP, Farnell M, Que FG, Reid-Lombardo K, Nagorney D, Kendrick ML,. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Oncologic advantages over open approaches? Ann Surg 2014; 260: 633-640.
15. Foley DP, Fernandez LA, Leverson G, et al., Donation after cardiac death: The University of Wisconsin experience with liver transplantation. Ann Surg 2005; 242: 724-731.
16. Klein AS, Messersmith EE, Ratner LE, et al., Organ donation and utilization in the United States, 1999-2008. Am J Transplant 2010; 10: 973.
17. Bellingham JM, Santhanakrishnan C, Neidlinger N, et al., Donation after cardiac death: A 29-year experience. Surgery 2011; 150: 692-702.
18. Dubbeld J, Hoekstra H, Farid W, et al., Similar liver transplantation survival with selected cardiac death donors and brain death donors. Br J Surg 2010; 97: 744-753.
19. Saidi RF, Bradley J, Greer D, et al., Changing pattern of organ donation at a single center: Are potential brain dead donors being lost to donation after cardiac death? Am J Transplantation 2010; 10: 2536-2540.
20. Perry DK, Willingham DL, Sibulesky L, Bulatao IG, Nguyen JH, Taner CB,. Should donation after cardiac death liver grafts be used for retransplantation? Ann Hepatol 2011; 10: 482-485.
21. Taner CB, Bulatao IG, Arasi LC, et al., Liver transplantation in the critically ill: Donation after cardiac death compared to donation after brain death grafts. Ann Hepatol 2012; 11: 679-685.
22. Wadei HM, Bulatao IG, Gonwa TA, et al., Inferior long-term outcomes of liver-kidney transplantation using donation after cardiac death donors: Single-center and organ procurement and transplantation network analyses. Liver Transpl 2014; 20: 728-735.
23. van der Bilt JD, Kranenburg O, Nijkamp MW, et al., Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005; 42: 165-175.
24. Doi K, Horiuchi T, Uchinami M, et al., Hepatic ischemia-reperfusion promotes liver metastasis of colon cancer. J Surg Res 2002; 105: 243-247.
25. Lee DD, Singh A, Burns JM, Perry DK, Nguyen JH, Taner CB,. Early allograft dysfunction in liver transplantation with donation after cardiac death donors results in inferior survival. Liver Transpl 2014; 20: 1447-1453.
26. Croome KP, Wall W, Quan D, et al., Evaluation of the updated definition of early allograft dysfunction in donation after brain death and donation after cardiac death liver allografts. Hepatobiliary Pancreat Dis Int 2012; 11: 372-376.
27. Nagai S, Yoshida A, Facciuto M, et al., Ischemia time impacts recurrence of hepatocellular carcinoma following liver transplantation. Hepatology 2015; 61: 895-904.